N/A N=54 Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis
Erosive Gastritis
Primary: Changes in Erosions — 4.36; 3.38; 2.32; 2.43 erosions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=305 Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
Non Erosive Reflux Disease · Chronic Gastritis
Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants
Phase 3 N=288 A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
Non-erosive Gastroesophageal Reflux Disease
Primary: Percentage of Participants With Complete Relief of Heartburn at Final Evaluation — 20.9; 34.4; 43.6 Percentage of participants
Phase 3 N=26 A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
Non-erosive Gastroesophageal Reflux Disease
Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…
N/A N=84 Effect of Chicken Egg Antibody (IgY) on Patients With Chronic Gastritis
Chronic Gastritis Caused by Helicobacter Pylori
Primary: UBT Values at Baseline and 8 Weeks — 161.64; 158.54; 49.42; 73.37 UBT value
N/A N=18 Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis
Eosinophilic Gastroenteritis
Primary: Percent of Participants in Complete Histologic Remission — 100 percentage of participants
Phase 3 N=26 Benralizumab for Eosinophilic Gastritis (BEGS)
Eosinophilic Gastritis or Gastroenteritis
Primary: Percent of Patients in Histological Remission (<30 Eos/Hpf) — 77; 8 percentage of participants — p=0.0001
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Phase 4 N=178 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers
Peptic Ulcer
Primary: Number of Participants in Whom Peptic Ulcer Was Healed — 66; 66 participants
N/A N=1,490 Blood Tests for Gastritis and Gastric Neoplasms
Cancer Screening Tests
Primary: Significant Blood Test Findings Correlated With Gastric Neoplasms — 9.9; 6.5 score on a scale
Phase 3 N=219 Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer
Gastric Ulcer
Primary: The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients…
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
Phase 3 N=51 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
Eosinophilic Esophagitis · Gastroesophageal Reflux Disease · EE
Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00
Phase 4 N=208 Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
Erosive Esophagitis
Primary: Number of Participants With Malignant Alteration of Epithelial Cells — 0; 0 Participants
N/A N=1,995 Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
Gastroesophageal Reflux Disease
Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale
Phase 3 N=471 Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Primary: Cumulative Recurrent Rates of Gastric or Duodenal Ulcers — 2.8; 1.4; 21.7 Events/100 participants/24 weeks — p=<0.001
Phase 4 N=301 Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Stomach Ulcer
Primary: Gastric Ulcer Healing Rate (Number of Subjects Whose Gastric Ulcer Was Healed/Number of Subjects Evaluated x 100) at Week 8 — 70.13; 60.54 percentage of participants
Phase 2 N=248 A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
Erosive Esophagitis
Primary: Number of Patients With Esophageal Mucosa Healing — 28; 28; 32; 18 Participants
Phase 2 N=41 Dupilumab in Eosinophilic Gastritis
Eosinophilic Gastritis · Eosinophilic Gastroenteritis
Primary: Relative Change of Peak Eosinophil Counts in the Stomach — -50.28; -3.54 Eosinophil per HPF (EOS/HPF)
N/A N=100 Gastric Ultrasound
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
Phase 3 N=572 Reflux Esophagitis Phase III Study (Initial Treatment)
Reflux Esophagitis
Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…
Phase 3 N=119 ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
Dyspepsia · Helicobacter Pylori Infection
Primary: The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing — 59; 1; 7; 36 Participants — p=0.001
Phase 3 N=405 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) — 77.1; 83.8 Percentage of participants
Phase 3 N=455 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
Helicobacter Pylori Infection · Dyspepsia
Primary: Number of Participants With Eradication of H. Pylori — 191; 131 Participants — p=0.0001
Phase 3 N=1,027 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
Erosive Esophagitis
Primary: Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8 — 92.9; 84.6 percentage of participants — p=<0.0001
Phase 2 N=65 A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Eosinophilic Gastritis · Eosinophilic Gastroenteritis
Primary: Percent Change in the Number of Eosinophils Per High Power Field in Gastric or Duodenal Mucosa From Baseline — -79; -92; -86; 9 Percentage of Change — p=<0.001
Phase 3 N=1,055 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD)
Primary: Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks — 75; 80; 20.3; 14.9 Percentage…
Phase 3 N=564 Reflux Esophagitis Phase III Study (Maintenance Treatment)
Reflux Esophagitis
Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants
Phase 3 N=2,054 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Esophagitis, Reflux · Esophagitis, Peptic
Primary: Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis. — 86.9; 89.4; 84.6 percentage of subjects…
Phase 3 N=311 Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
Stress Ulcer Prophylaxis
Primary: The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase — 2.7; 4.6 % of participants — p=0.393